Decreased cGMP level contributes to increased contraction in arteries from hypertensive rats: Role of phosphodiesterase 1

Hypertension

Volumn 57, Issue 3 PART 2, 2011, Pages 655-663

  Giachini, Fernanda R ^a   Lima, Victor V ^a,b   Carneiro, Fernando S ^a,b   Tostes, Rita C ^a,b   Webb, R Clinton ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

angiotensin II; cGMP; hypertension; vinpocetine

Indexed keywords

ANGIOTENSIN II; CYCLIC GMP; PHENYLEPHRINE; PHOSPHODIESTERASE 1A; PHOSPHODIESTERASE 1C; PHOSPHODIESTERASE I; SILDENAFIL; UNCLASSIFIED DRUG; VINPOCETINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY CONSTRICTION; ARTICLE; BIOAVAILABILITY; BLOOD PRESSURE; CONTROLLED STUDY; ENZYME INHIBITION; HYPERTENSION; MALE; MESENTERIC ARTERY; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; UPREGULATION; VASOCONSTRICTION; VASODILATATION;

ANALYSIS OF VARIANCE; ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIES; BLOOD PRESSURE; BLOTTING, WESTERN; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTENSION; MALE; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; RATS; RATS, SPRAGUE-DAWLEY; SULFONES; VASOCONSTRICTION; VINCA ALKALOIDS;

EID: 79953215598     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.164327     Document Type: Article

References (42)

1. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res. 2003;93: 280-291. (Pubitemid 37048240)
2. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther. 2006;109:366-398. (Pubitemid 43132818)
3. Surks HK, Mochizuki N, Kasai Y, Georgescu SP, Tang KM, Ito M, Lincoln TM, Mendelsohn ME. Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase Ialpha. Science. 1999;286:1583-1587.
4. Beavo JA, Brunton LL. Cyclic nucleotide research-still expanding after half a century. Nat Rev Mol Cell Biol. 2002;3:710-718. (Pubitemid 34987792)
5. Schlossmann J, Ammendola A, Ashman K, Zong X, Huber A, Neubauer G, Wang GX, Allescher HD, Korth M, Wilm M, Hofmann F, Ruth P. Regulation of intracellular calcium by a signalling complex of IRAG, IP3 receptor and cGMP kinase Ibeta. Nature. 2000;404:197-201. (Pubitemid 30154489)
6. Miller CL, Oikawa M, Cai Y, Wojtovich AP, Nagel DJ, Xu X, Xu H, Florio V, Rybalkin SD, Beavo JA, Chen YF, Li JD, Blaxall BC, Abe J, Yan C. Role of Ca2/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. Circ Res. 2009; 105:956-964.
7. Koyama H, Bornfeldt KE, Fukumoto S, Nishizawa Y. Molecular pathways of cyclic nucleotide-induced inhibition of arterial smooth muscle cell proliferation. J Cell Physiol. 2001;186:1-10.
8. Sonnenburg WK, Rybalkin SD, Bornfeldt KE, Kwak KS, Rybalkina IG, Beavo JA. Identification, quantitation, and cellular localization of PDE1 calmodulin-stimulated cyclic nucleotide phosphodiesterases. Methods. 1998;14:3-19.
9. Huang CY, Chau V, Chock PB, Wang JH, Sharma RK. Mechanism of activation of cyclic nucleotide phosphodiesterase: requirement of the binding of four Ca2 to calmodulin for activation. Proc Natl Acad Sci USA. 1981;78:871-874. (Pubitemid 11159528)
10. Wells JN, Baird CE, Hardman YJ, Wu JG. Cyclic nucleotide phosphodiesterase activities of pig coronary arteries. Biochim Biophys Acta. 1975;384:430-442.
11. Schermuly RT, Pullamsetti SS, Kwapiszewska G, Dumitrascu R, Tian X, Weissmann N, Ghofrani HA, Kaulen C, Dunkern T, Schudt C, Voswinckel R, Zhou J, Samidurai A, Klepetko W, Paddenberg R, Kummer W, Seeger W, Grimminger F. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. Circulation. 2007;115:2331-2339. (Pubitemid 46685901)
12. Touyz RM. Recent advances in intracellular signalling in hypertension. Curr Opin Nephrol Hypertens. 2003;12:165-174. (Pubitemid 36288317)
13. Rybalkin SD, Rybalkina I, Beavo JA, Bornfeldt KE. Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation. Circ Res. 2002;90:151-157. (Pubitemid 34627083)
14. Kim D, Aizawa T, Wei H, Pi X, Rybalkin SD, Berk BC, Yan C. Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling. J Mol Cell Cardiol. 2005;38:175-184. (Pubitemid 40038664)
15. Ahn HS, Crim W, Romano M, Sybertz E, Pitts B. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem Pharmacol. 1989;38:3331-3339. (Pubitemid 19254124)
16. Hagiwara M, Endo T, Hidaka H. Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem Pharmacol. 1984; 33:453-457. (Pubitemid 14163168)
17. Souness JE, Brazdil R, Diocee BK, Jordan R. Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine. Br J Pharmacol. 1989;98:725-734. (Pubitemid 19269794)
18. Evgenov OV, Busch CJ, Evgenov NV, Liu R, Petersen B, Falkowski GE, Petho B, Vas A, Bloch KD, Zapol WM, Ichinose F. Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2006;290:L723-L729. (Pubitemid 43725077)
19. Montorsi F, Corbin J, Phillips S. Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention. J Sex Med. 2004;1:322-336. (Pubitemid 40424643)
20. Priviero FB, Jin LM, Ying Z, Teixeira CE, Webb RC. Up-regulation of the RhoA/Rho-kinase signaling pathway in corpus cavernosum from endothelial nitric-oxide synthase (NOS), but not neuronal NOS, null mice. J Pharmacol Exp Ther. 333:184-192.
21. Teixeira CE, Priviero FB, Webb RC. Effects of 5-cyclopropyl-2-[1-(2- fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-4-ylamine (BAY 41-2272) on smooth muscle tone, soluble guanylyl cyclase activity, and NADPH oxidase activity/expression in corpus cavernosum from wild-type, neuronal, and endothelial nitric-oxide synthase null mice. J Pharmacol Exp Ther. 2007;322:1093-1102. (Pubitemid 47295787)
22. Touyz RM. Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II. Curr Opin Nephrol Hypertens. 2005; 14:125-131. (Pubitemid 40396865)
23. Schmidt-Ott KM, Kagiyama S, Phillips MI. The multiple actions of angiotensin II in atherosclerosis. Regul Pept. 2000;93:65-77.
24. Kemp-Harper B, Schmidt HH. cGMP in the vasculature. Hand Exp Pharmacol. 2009;447-467.
25. Yan C, Kim D, Aizawa T, Berk BC. Functional interplay between angiotensin II and nitric oxide: cyclic GMP as a key mediator. Arterioscler Thromb Vasc Biol. 2003;23:26-36. (Pubitemid 36091622)
26. Komalavilas P, Lincoln TM. Phosphorylation of the inositol 1,4,5-trisphosphate receptor by cyclic GMP-dependent protein kinase. J Biol Chem. 1994;269:8701-8707. (Pubitemid 24209175)
27. Sauzeau V, Le Jeune H, Cario-Toumaniantz C, Smolenski A, Lohmann SM, Bertoglio J, Chardin P, Pacaud P, Loirand G. Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2 sensitization of contraction in vascular smooth muscle. J Biol Chem. 2000;275: 21722-21729.
28. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, Waldman SA. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev. 2000;52:375-414.
29. Saito S, Hirata Y, Emori T, Imai T, Marumo F. Angiotensin II activates endothelial constitutive nitric oxide synthase via AT1 receptors. Hypertens Res. 1996;19:201-206.
30. Olson SC, Dowds TA, Pino PA, Barry MT, Burke-Wolin T. ANG II stimulates endothelial nitric oxide synthase expression in bovine pulmonary artery endothelium. Am J Physiol. 1997;273:L315-L321.
31. Mollnau H, Wendt M, Szöcs K, Lassègue B, Schulz E, Oelze M, Li H, Bodenschatz M, August M, Kleschyov AL, Tsilimingas N, Walter U, Förstermann U, Meinertz T, Griendling K, Münzel T. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res. 2002;90: E58-E65.
32. Haneda M, Kikkawa R, Maeda S, Togawa M, Koya D, Horide N, Kajiwara N, Shigeta Y. Dual mechanism of angiotensin II inhibits ANPinduced mesangial cGMP accumulation. Kidney Int. 1991;40:188-194.
33. Kim SM, Byun JS, Jung YD, Kang IC, Choi SY, Lee KY. The effects of oxygen radicals on the activity of nitric oxide synthase and guanylate cyclase. Exp Mol Med. 1998;30:221-226.
34. Weber M, Lauer N, Mülsch A, Kojda G. The effect of peroxynitrite on the catalytic activity of soluble guanylyl cyclase. Free Radic Biol Med. 2001;31:1360-1367. (Pubitemid 33145305)
35. Kim D, Rybalkin SD, Pi X, Wang Y, Zhang C, Munzel T, Beavo JA, Berk BC, Yan C. Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation. 2001;104:2338-2343. (Pubitemid 33049518)
36. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev. 2000;52:639-672.
37. Schermuly RT, Inholte C, Ghofrani HA, Gall H, Weissmann N, Weidenbach A, Seeger W, Grimminger F. Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. Respir Res. 2005;6:76.
38. Jeon KI, Xu X, Aizawa T, Lim JH, Jono H, Kwon DS, Abe J, Berk BC, Li JD, Yan C. Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc Natl Acad Sci USA. 107:9795-9800.
39. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006;58:488-520. (Pubitemid 44394910)
40. Rybalkin SD, Bornfeldt KE, Sonnenburg WK, Rybalkina IG, Kwak KS, Hanson K, Krebs EG, Beavo JA. Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J Clin Invest. 1997;100: 2611-2621. (Pubitemid 27514902)
41. Palmer D, Maurice DH. Dual expression and differential regulation of phosphodiesterase 3A and phosphodiesterase 3B in human vascular smooth muscle: implications for phosphodiesterase 3 inhibition in human cardiovascular tissues. Mol Pharmacol. 2000;58:247-252. (Pubitemid 30497467)
42. Linder AE, Leite R, Lauria K, Mills TM, Webb RC. Penile erection requires association of soluble guanylyl cyclase with endothelial caveolin-1 in rat corpus cavernosum. Am J Physiol Regul Integr Comp Physiol. 2006;290:R1302-R1308.